News & Media
News Updates
NEW YORK, May 23, 2024 — Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today unveiled key performance

Innovative Fingerprint Drug Screening Solution Showcased at the UK’s Premier Health and Safety Event
NEW YORK, May 17, 2024 — Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful
Year-over-year revenue increased 80% for the fiscal third quarter and 193% for the nine months ended March 31, 2024. Cash and cash equivalents as of March 31, 2024, was $9.40 million. Commenced FDA 510(k) clinical
Traditional drug tests can be intrusive, undignified, and uncomfortable for both test takers and administrators. The Intelligent Fingerprinting Drug Screening System detects commonly abused drugs via fingertip sweat analysis, eliminating the need for invasive and unpleasant urine, saliva, or blood collection.
Year-over-year unaudited revenue increased 80% for the fiscal third quarter and 193% for the nine months ended March 31, 2024, with highest quarterly cartridge sales since 2022 Intelligent Fingerprinting acquisition
Non-invasive health diagnostics are on the rise, and fingerprint testing technology is at the forefront. This article explores the history and ongoing development of fingerprint sweat analysis and its potential
NEW YORK, April 11, 2024 – Intelligent Bio Solutions Inc. (“INBS” or the “Company”) (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the broadening
NEW YORK, February 28, 2024 – Intelligent Bio Solutions Inc. (“INBS” or the “Company”) (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its partnership
NEW YORK, February 16, 2024 – Intelligent Bio Solutions Inc. (“INBS” or the “Company”) (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that on
Year-over-year revenue increased 114% for the fiscal second quarter and 337% for the six-months ending December 31, 2023. Expanded into New Zealand market and increased market share in existing regions.
Year-over-year unaudited revenue increased 114% for the fiscal second quarter and 337% for the six months ended December 31, 2023 NEW YORK, February 02, 2024 — Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS”
Customers identify in-house control, project flexibility, productivity, and cost reductions as key business benefits of fingerprint drug testing
Media














